Written by Zane McNeill, Civil Rights & Health Equity Legal Fellow at L4GG —The Supreme Court may once again decide the future of mifepristone access, as a wave of state-led legal challenges threatens not only abortion medication but the FDA's broader authority to regulate drugs nationwide.
Why Reproductive Justice and Trans Liberation Are One Fight
Written by Zane McNeill, Civil Rights & Health Equity Legal Fellow at L4GG — reproductive justice and transgender liberation are not separate fights: they share the same core principle of bodily autonomy and face the same coordinated political attacks, making solidarity between movements not just important but essential.
Texas’ Attack on a Latina Midwife Extends a Legacy of Racialized Policing of Care
Written by Zane McNeill, Civil Rights & Health Equity Legal Fellow at L4GG — the prosecution of Maria Margarita Rojas, a Houston-area Latina midwife who served uninsured, Spanish-speaking patients, is the first criminal case under Texas's abortion ban and echoes a long history of racialized attacks on midwives of color.
There Is No Bodily Autonomy Without Defunding ICE
Written by Zane McNeill, Civil Rights & Health Equity Legal Fellow at L4GG — true bodily autonomy is impossible alongside state violence: with 73,000 people detained in ICE facilities, documented medical neglect, and entire communities afraid to seek healthcare, immigration enforcement is itself a public health crisis.
Do Human Rights Extend to Transgender Americans?
Written by Allison Chapman, Civil Rights & Health Equity Project Fellow at L4GG — after the Supreme Court allowed the Trump administration to reinstate its passport policy stripping accurate gender markers from transgender, nonbinary, and intersex Americans, hundreds of thousands face restricted freedom of movement, leaving many wondering whether their fundamental human rights still apply.
How Attorneys Can Help Combat Pregnancy Criminalization
Mifepristone Under Attack
Written by Zane McNeill, Civil Rights & Health Equity Legal Fellow at L4GG — approved by the FDA 25 years ago and used in nearly two-thirds of U.S. abortions, mifepristone is now under coordinated attack from anti-abortion states and the Trump administration, which is using agency review as a potential backdoor to restrict or ban the medication nationwide.





